CDCN Community Update: click here.
KEY HHV-8-NEGATIVE OR IDIOPATHIC MCD ARTICLES:
Fajgenbaum D, et al. "International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease." Blood. 2017. (full-text). **CDCN led**
Li Y, et al. "Clinical and pathological charactersistics of HIV- and HHV8- negative Castleman disease." Blood. 2017. (full-text). **CDCN co-led**
Liu A et al "Idiopathic multicentric Castleman's disease: a systematic literature review." Lancet Haematology. 2016. (full-text) **CDCN led**
Fajgenbaum D, van Rhee F, Nabel C. "HHV-8-negative or idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and treatment." Blood. 2014; 123(19): 2924-2933. (full-text) **CDCN led**
Fajgenbaum D, Ruth J, Kelleher D, Rubenstein A. "The collaborative network approach: a new framework for accelerating Castleman's disease and other rare disease research." Lancet Haematology. 2016. (full-text) **CDCN led**
- To access the above article translated into Portuguese, please click here.
Newman S at al. "Taking Control of Castleman disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research." Yale Journal of Biology & Medicine. 2015. (full-text) **CDCN led**
LARGEST HHV-8-NEGATIVE MCD PLUS TAFRO SYNDROME SERIES:
Noriko Iwaki, David C. Fajgenbaum, Christopher S. Nabel, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. American Journal of Hematology 2016. 2016; 91:220–226. (full-text) **CDCN co-led**
KEY HHV-8-ASSOCIATED MCD REVIEW ARTICLES:
Thomas S Uldrick, Mark N Polizzotto, Robert Yarchoan. "Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease." Current Opinion in Oncology. 2012; 24(5):495-505
KEY UCD REVIEW ARTICLES:
Bowne W, et al. "The Management of Unicentric and Multicentric Castleman’s Disease: A Report of 16 Cases and a Review of the Literature." Cancer. 1999; 85(3): 706-717.
KEY GENERAL CD REVIEW ARTICLES:
van Rhee F, Fajgenbaum D. "Ask the Hematologist: Treatment of Castleman disease." The Hematologist. 2015; 2(12):4-5. **CDCN led**
van Rhee F, et al. "Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy." Clin Adv Hematol Oncol. 2010; 8(7):486-98.
KEY PEDIATRIC CD ARTICLES:
Jun Z, et al. "Clinical and Experimental Study of Castleman Disease in Children." Pediatric Blood & Cancer. 2014. DOI 10.1002/pbc
IMPORTANT RESEARCH PUBLICATIONS:
Kunch-Choa Chang et al. "Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease." Modern Pathology. 2014; 27(6):823-831.
Stone K et al. "Interleukin-6 Receptor Polymorphism Is Prevalent in HIV- negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels." PLOS one. 2013; 8(1):e54610. (full-text)
Siltuximab (only FDA- and EMA-approved treatment for HHV-8-negative MCD)
van Rhee F, et a. "Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial." The Lancet Oncology. 2014; 15(9): 966-974.
Markham A, Patel T. "Siltuximab: first global approval." Drugs. 2014; 74(10): 1147-1152.
Fajgenbaum D, Kurzrock R. "Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease." Immunotherapy. 2016; 8(1), 17–26.
Kurzock R et al. "A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease." Clin. Cancer Res. 2013; 19(13): 3659-3670.
Tocilizumab (only Japanese Ministry of Health & Welfare-approved therapy for MCD)
Turcotte LM et al. "Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance." Pediatric Blood Cancer. 2014; 61(4): 737-739.
Matsuyama M et al. "Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multricentric Castleman's disease." Intern Med. 2007; 46(11):771-774.
Nishimoto N. "Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease." Blood. 2005. 106(8):2627-2632.
Other/Off-Label Therapies (not approved for use in Castleman disease)
El-Osta H, Janku F, Kurzrock R. "Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra)." Mol. Cancer Ther. 2010; 9(6):1485-1488.
OTHER KEY PUBLICATIONS:
Behnia F, Elojeimy S, Matesan M, Fajgenbaum D. "Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome." Ann Hematol. 2016. (full-text) **CDCN co-led**
Fajgenbaum D, et al. "Eruptive cherry hemangiomatosis associated with multicentric Castleman disease." JAMA Dermatology. 2013. (full-text) **CDCN led**
Dong Y, et al. " Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor." British Journal of Haematology. 2015. (full-text)
**Abbreviations: UCD = unicentric Castleman disease, MCD = multicentric Castleman disease, CD = Castleman disease, HHV-8 = Human Herpes Virus-8**